What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
His primary areas of investigation include Internal medicine, Transplantation, Surgery, Immunology and Hematopoietic stem cell transplantation.
His Internal medicine research includes elements of Gastroenterology and Oncology.
His work carried out in the field of Transplantation brings together such families of science as Survival rate, Transplantation Conditioning, Total body irradiation and Immunosuppression.
His Surgery research is multidisciplinary, relying on both Cancer, Comorbidity, Rituximab and Hazard ratio.
His Hematopoietic stem cell transplantation study also includes fields such as
- Incidence which connect with Aspergillosis,
- Proportional hazards model which is related to area like Clinical trial and Cause of death.
His Leukemia study which covers Myeloid that intersects with Myeloid leukemia.
His most cited work include:
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. (1740 citations)
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. (1740 citations)
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma (1540 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Transplantation, Oncology, Surgery and Fludarabine.
His Internal medicine study frequently intersects with other fields, such as Gastroenterology.
His research in Transplantation intersects with topics in Immunosuppression, Immunology and Hazard ratio.
As a part of the same scientific study, David G. Maloney usually deals with the Oncology, concentrating on Follicular lymphoma and frequently concerns with Diffuse large B-cell lymphoma.
David G. Maloney has researched Surgery in several fields, including Multiple myeloma and Comorbidity.
His Hematopoietic stem cell transplantation study combines topics from a wide range of disciplines, such as Survival rate, Retrospective cohort study, Transplantation Conditioning, Leukemia and Survival analysis.
He most often published in these fields:
- Internal medicine (106.67%)
- Transplantation (77.33%)
- Oncology (56.27%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (106.67%)
- Oncology (56.27%)
- Lymphoma (25.87%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Lymphoma, Fludarabine and Transplantation.
His studies in Internal medicine integrate themes in fields like Gastroenterology and B cell.
As part of the same scientific family, he usually focuses on Gastroenterology, concentrating on Cohort and intersecting with Regimen.
His research integrates issues of Relapsed refractory, Refractory, Diffuse large B-cell lymphoma and Indolent Non-Hodgkin Lymphoma in his study of Oncology.
His Fludarabine research incorporates elements of Myeloid leukemia and Sirolimus.
David G. Maloney interconnects Total body irradiation and Rituximab in the investigation of issues within Transplantation.
Between 2018 and 2021, his most popular works were:
- Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. (101 citations)
- Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. (101 citations)
- The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. (76 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
David G. Maloney focuses on Internal medicine, Oncology, Chimeric antigen receptor, Lymphoma and Immunotherapy.
His Internal medicine research includes themes of Gastroenterology and B cell.
His Oncology study combines topics in areas such as Hematopoietic stem cell transplantation, Leukemia, Minimal residual disease, Relapsed refractory and Salvage therapy.
The study incorporates disciplines such as Cancer research, Cell therapy and Antigen in addition to Chimeric antigen receptor.
His Immunotherapy research is multidisciplinary, incorporating elements of Epitope, Antibody and Chemotherapy.
His work on Graft-versus-host disease as part of general Transplantation research is frequently linked to Multicenter trial, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
